Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder
Sponsor: University Hospital, Toulouse
Summary
The main objective of this pilot study is to evaluate at D9 the evolution of BPD symptoms' intensity(scale BSL-23) in severe BPD patients, after two Ketamine infusions (0.5mg/kg at H0 and H24). The intervention is combined with the first level standard of care : Good Psychiatric Management (GPM). Patients are followed up to 3 months by regular visits conducted by a psychiatrist. Secondary outcomes are monitored including BPD symptoms at different times, suicidal ideation, depressiv symptoms, healthcare use and adverse effects.
Official title: Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder: A Pilot Study
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
38
Start Date
2025-11-01
Completion Date
2027-12-31
Last Updated
2025-08-11
Healthy Volunteers
No
Conditions
Interventions
IV Ketamine (0.5 mg/kg) Infusion - Two Doses Administered 24 Hours Apart for Severe Borderline Personality Disorder
Participants receive two intravenous (IV) infusions of ketamine at a dose of 0.5 mg/kg over 40 minutes. The first infusion is administered at Hour 0 (H0) and the second at Hour 24 (H24). Vital signs and potential adverse effects are closely monitored before, during, and after each infusion. This intervention aims to assess the short-term efficacy and safety of ketamine in reducing symptoms of severe borderline personality disorder.
Locations (1)
Toulouse Purpan University Hospital, Head of Psychiatry Clinic in the UF3 department
Toulouse, France